Alcidion's New U.K. Contract Validates Acquisition
Dow Jones
5 hours ago
0031 GMT - Alcidion's new contract within the U.K. National Health Service is seen by Bell Potter as validating the healthcare software provider's 2021 ExtraMed acquisition. Analyst Thomas Wakim says in a note that the contract upgrades the NHS body's existing ExtraMed product, reinforcing the value proposition of Alcidion's internally developed product in the U.K. market. With an unchanged buy rating on the stock, Wakim points out that there is further upside potential if additional contract options are executed. Bell Potter holds its target price at 0.15 Australian dollars. Shares are flat at A$0.11.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.